Literature DB >> 27880985

Daily pain in adults with sickle cell disease-a different perspective.

Charlotte F J van Tuijn1, Joep W R Sins1,2, Karin Fijnvandraat2, Bart J Biemond1.   

Abstract

Previous reports demonstrated that patients with sickle cell disease (SCD) experience pain on more than half of the observed days. Yet, these high incidences do not seem to match observations in our population. In this prospective cohort study, we aimed to assess the frequency and characteristics of daily, self-reported pain among adult SCD patients in the Netherlands. Consecutive patients were enrolled during routine outpatient visits and followed up to 6 months. A total of 55 patients completed 5,982 diary observation days. Median age was 27 years (IQR 23-43). Patients reported SCD related pain on 17% of the observed days; on 13% of these days this pain was not defined as a painful crisis, while 3% was reported as a painful crisis but managed at home, and on 1% of the observed days patients were admitted to the hospital. Analgesics were used on 52% of days with pain with a relatively infrequent use of oral opioids (9% of pain days). This first European study on pain in SCD indicates that pain appears to be significantly less frequent in our population as compared to previous study cohorts from the United States, and may be more representative for current SCD populations in other Western countries. Besides a more widespread use of hydroxycarbamide in modern disease management, differences in organization and accessibility of healthcare between countries may also explain this discrepancy.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27880985     DOI: 10.1002/ajh.24612

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.

Authors:  Joep W R Sins; David J Mager; Shyrin C A T Davis; Bart J Biemond; Karin Fijnvandraat
Journal:  Blood Adv       Date:  2017-08-22

2.  Characterization of opioid use in sickle cell disease.

Authors:  Jin Han; Jifang Zhou; Santosh L Saraf; Victor R Gordeuk; Gregory S Calip
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-08-16       Impact factor: 2.890

3.  Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project.

Authors:  Wally R Smith; Donna K McClish; James Levenson; Imoigele Aisiku; Bassam Dahman; Viktor E Bovbjerg; Susan Roseff; John Roberts
Journal:  Pain Med       Date:  2018-10-01       Impact factor: 3.750

4.  Do chronic pain and comorbidities affect brain function in sickle cell patients? A systematic review of neuroimaging and treatment approaches.

Authors:  Joyce T Da Silva; Janelle E Letzen; Jennifer A Haythornthwaite; Patrick H Finan; Claudia M Campbell; David A Seminowicz
Journal:  Pain       Date:  2019-09       Impact factor: 7.926

5.  Trajectories of Biological Values and Vital Parameters: An Observational Cohort Study of Adult Patients with Sickle Cell Disease Hospitalized for a Non-Complicated Vaso-Occlusive Crisis.

Authors:  Raphael Veil; Simon Bussy; Vincent Looten; Jean-Benoît Arlet; Jacques Pouchot; Anne-Sophie Jannot; Brigitte Ranque
Journal:  J Clin Med       Date:  2019-09-19       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.